As eyewear retailer Lenskart gears up for a high-profile IPO, a regulatory shadow is beginning to loom large over the company’s international ambitions. A little-discussed Enforcement Directorate (ED) investigation, flagged in the company’s own draft IPO papers, has emerged as a critical hurdle for its global expansion plans, according to a widely circulated post by market commentator Jayant Mundhra.
While public attention has remained fixed on the founder’s controversies and the hype around the public issue, the ED scrutiny could prove more consequential for Lenskart’s future than any social-media storm.
Under ED Scanner, Overseas Deals Need Permission Slip
As per disclosures cited in the post, Lenskart is currently being probed by the ED for “procedural delays” and alleged FEMA-related lapses. The direct consequence of this is significant: the company must obtain a No-Objection Certificate (NOC) from the ED every time it wants to make an overseas direct investment.
In simple terms:
- Lenskart needs the ED’s nod before buying or funding any foreign company.
- This also applies to its existing international subsidiaries, including those it has already acquired.
This means the same agency investigating the company is also the gatekeeper for its global operations.
NOC Requests Rejected Twice, Says Post
According to Mundhra’s analysis, Lenskart’s NOC requests have been turned down twice by the ED, a detail that has drawn little public attention but carries heavy implications. Overseas acquisition has been a key plank in Lenskart’s vision of becoming a global eyewear brand.
A rejection of such permissions signals a potential choke point in that strategy.
How Deals Still Went Through: A Legal Loophole
Despite the scrutiny, the company has continued to expand overseas, including its investment in Spanish eyewear brand Meller. This, as per the post, has been made possible through a “deemed granted” provision in India’s overseas investment rules.
Under this mechanism:
- If the ED does not respond within a stipulated time,
- the NOC is treated as granted by default,
- allowing the company to proceed with the transaction.
The provision is legal, but the dependence on it, especially while under investigation, raises concerns about how future deals may unfold.
Lenskart Warns Investors in DRHP
Importantly, the company itself acknowledges this uncertainty in its draft red herring prospectus (DRHP). As quoted in the post, the document cautions:
“While our Company has availed this provision in the past, we cannot assure you that we will be able to continue doing so in the future.”
This admission turns an abstract regulatory issue into a concrete business risk, one that could directly shape the company’s valuation.
Premium Valuation, Hidden Risk
Lenskart’s pitch to investors hinges heavily on its global footprint. But critics argue that a strategy built on a “deemed approval” clause and dependent on a regulator’s silence, should ordinarily warrant a discount, not a premium.
The company’s showcase narrative of international scale, they point out, sits uneasily beside disclosures acknowledging ED scrutiny and blocked permissions.
Bull vs Bear: Two Readings of the Same Risk
Analysts tracking the issue outline two contrasting scenarios:
The optimistic view:
The investigation may be a procedural hurdle. Once settled, Lenskart may simply pay penalties and face stricter compliance, without long-term damage to its operations.
The pessimistic view:
Lenskart’s global strategy effectively survives at the discretion of the ED. Any tightening by the regulator could bring new deals to a halt. In that case, the expansion story that fuels its valuation could be significantly weakened.
A Risk Overshadowed by Noise
The post highlights how the founder-related controversy consumed public attention, while the ED-related disclosures, arguably more material to investors, barely made news.
Whether by coincidence or design, the focus stayed on personality-driven drama rather than the regulatory compliance issues with direct implications for Lenskart’s IPO and long-term strategy.
